fashion -WSS

fashion

author：comprehensive 2025-10-02 10:45:26 - browse：12189

Apellis Pharmaceuticals said Tuesday that it had identified “internal structural variations” in a type of needle used by doctors to prepare syringes of its eye disease drug Syfovre as a possible cause of severe eye inflammation reported in patients receiving the treatment — but the company stopped short of definitively linking the needle to the cases.

Additionally, Apellis confirmed one additional case of the severe and potentially blinding side effect, known as retinal occlusive vasculitis, or ROV, that occurred in May. But with thousands of more Syfovre eye injections also performed, the overall frequency of ROV remains unchanged and rare, even with the added scrutiny and increased physician monitoring.

Apellis shares rose 30% to $40 in Wednesday’s pre-market trading on the growing belief amongst investors that Syfovre’s safety crisis is abating.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： Pioneering cancer drug will cost $475,000. Analysts call it a bargain

WSS

Cancer, immunology, HIV research ensnared in fetal tissue politics

Correcting Robert F. Kennedy Jr.'s vaccine 'facts'

Science's Marcia McNutt, trailblazer for women, encounters sexism scandal

Readout Newsletter: Illumina, CRISPR, Regeneron

Inside the rise of 'mukbang' eating videos

Medicare Advantage insurers pressure Biden for bigger payments

explore

fashion

Wikipedia

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Testing GLP

Duchenne breakthrough therapy leaves behind pioneering families

Biogen nominates mother of director’s child to replace him on board

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Novo pauses ads for weight loss drug Wegovy amid demand

Moonlake's readout produced a cash windfall. Risks remain

Timeline: Key moments in fight for gay rights

Peter Hotez and the public health issue of online harassment

Ibogaine psychedelic therapy for opioid addiction unlikely, official says

hotspot

This gene therapy has record $4.25 million price. It's saved children.

How to fix the rural physician shortage in the U.S.

6 surprising facts about sugar

Testing GLP

Testing GLP

FDA approves first new drug developed for postpartum depression

explore

explore

focus

focus